KERENDIA® (finerenone) Meets Primary Endpoint in Investigational Phase III FIND-CKD Study in Patients with Non-Diabetic Chronic Kidney Disease

The Phase III study FIND-CKD (NCT05047263) — investigating the efficacy and safety of KERENDIA® (finerenone) versus placebo when added to standard of care in adult patients with non-diabetic chronic ...

Annovis Bio Inc.: Annovis Provides Corporate Updates and Reports Fiscal Year 2025 Financial Results

Annovis Bio, Inc. (NYSE: ANVS) ("Annovis" or the "Company"), a Phase 3 clinical-stage biotechnology company developing the investigational oral therapy ...

KE Holdings Inc. Announces Fourth Quarter and Fiscal Year 2025 Unaudited Financial Results and a Final Cash Dividend

KE Holdings Inc. ("Beike" or the "Company") (NYSE: BEKE; HKEX: 2423), a leading integrated online and offline platform for housing transactions and services ...
BMJ Global Health

Implementation of essential newborn care in settings of high-intensity armed conflict: a systematic review

Introduction A disproportionate share of global neonatal deaths occurs in armed-conflict settings, where progress in reducing neonatal mortality remains slow. This systematic review aims to synthesise ...